WUXI BIO (02269) added 151 new comprehensive projects in 2024 and is expected to achieve accelerated growth in 2025.

According to the latest company announcement from WUXI BIO (02269) on January 13th, the number of new comprehensive projects in 2024 is 151, reaching a total of 817 projects, setting a new historical high and showcasing the strong business momentum and continuous growth capability of the company. As of now, the research service projects have reached over 50, reaching a turning point after years of deep cultivation. Through cooperation to drive innovation, it has opened up new space for revenue and profit growth. In 2024, the company signed 148 new development projects, with continuous revenue growth. Through excellent execution and fast delivery, project progress has been accelerated. The company currently has 87 Phase III clinical and commercialization projects, injecting strong momentum for future business growth. In 2024, 16 PPQs were completed, with an expected 24 PPQs in 2025, accelerating revenue growth compared to 2024. The strong growth exceeds expectations, with repairable value opportunities.